1. Introduction {#s0005}
===============

Infection with influenza during pregnancy and its association with adverse birth outcomes has been documented since the early 1900s [@b0005], [@b0010]. For instance, infection with influenza virus during pregnancy may prompt an inflammatory \[cascade\] response that is associated with preterm birth [@b0015], [@b0020]. Influenza vaccination has been shown to reduce the risk of influenza virus disease and its complications among pregnant women and their infants [@b0025], [@b0030], [@b0035], [@b0040], [@b0045], [@b0050], [@b0055], [@b0060], [@b0065], [@b0070], [@b0075]. Furthermore, some studies have found a beneficial effect of influenza vaccination on birth outcomes, specifically a decreased likelihood of delivering a baby preterm or small for gestational age [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105], [@b0110]. Other studies, however, have found no evidence to support this hypothesis [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0145], [@b0150]. Published studies have differed substantially from one another in design and in ability to account for variations in circulating influenza viruses, vaccine components, target population, and place of study, making cross-study comparisons difficult [@b0155].

Historic influenza surveillance data from Nicaragua shows that influenza circulates between June and November [@b0160]. Since 2007, the Nicaraguan Government has provided influenza vaccination to women with high-risk pregnancies in the month of May, following the vaccination schedule for countries with southern hemisphere circulation of influenza viruses [@b0165], [@b0170]. In May 2014, Nicaragua expanded influenza vaccination to all pregnant women in the country. With the aim of evaluating the hypothesis that influenza vaccination has a beneficial effect on birth outcomes, we collected birth outcome data, current influenza vaccination status, and risk factors for adverse pregnancy outcomes by interviewing post-partum women at two large hospitals in Managua.

2. Methods {#s0010}
==========

2.1. Survey {#s0015}
-----------

### 2.1.1. Sample size calculation {#s0020}

Sample size planning was informed by calculating sample needs in order to detect a 40% reduction of low birth weight among newborns of vaccinated (regardless of vaccination trimester) compared to unvaccinated mothers [@b0100], [@b0105], assuming a two-sided 95% confidence level, 80% power, and a ratio of unvaccinated to vaccinated of 2:5 [@b0165]. A design effect of 1.5 was considered to account for any potential biases. The sample size required was estimated to be 2769 (1938 vaccinated and 831 unvaccinated pregnant women).

### 2.1.2. Inclusion criteria {#s0025}

We selected two large public hospitals, Hospital Aleman Nicaragüense and Hospital Bertha Calderon Roque. Inclusion criteria were being a resident of the Department of Managua and having a singleton birth. Exclusion criteria were delivering a stillborn or newborn with congenital or neonatal anomalies, receiving influenza vaccination before May 1st, 2014 -the start date for the national influenza vaccination campaign [@b0160]- or less than 14 days before delivery, and having a gestational age \<28 or \>42 weeks at delivery which are the viability and post-term cut-offs, respectively [@b0175], [@b0180]. The study was designed as an observational study where a cohort of women who provided informed consent were interviewed between July 21st and December 4th 2014, within 48 h after delivery. Participants were selected in a convenience manner.

### 2.1.3. Questionnaire {#s0030}

The questionnaire included demographic information (age, race, living environment, education level, type of fuel used for cooking, number of persons in the household, delivery hospital), antenatal care (number of antenatal visits, vaccinations received during pregnancy, consumption of antenatal supplements), presence of medical conditions prior to pregnancy (obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease), any complications during pregnancy (hospitalization for any specific complication such as preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection, or influenza-like illness), other risk factors for adverse pregnancy outcomes (alcohol consumption and smoking before and during pregnancy), obstetric characteristics of the mother (number of parturitions, number of abortions, number of livebirths and stillbirths, type of delivery), and characteristics of the offspring (sex, weight, gestational age at delivery). Pregnancy and birth outcome data were obtained from antenatal and hospital medical records and included date of last menstrual period (LMP), gestational age calculated by ultrasound when LMP was not available from antenatal medical records, delivery date, and birth weight. Influenza vaccination was self-reported; however, interviewers validated this information using vaccination cards and/or antenatal medical records if available.

### 2.1.4. Assessing self-reported influenza vaccination {#s0035}

We assessed the validity of self-reporting influenza vaccination or non-vaccination through random sampling of the self-reported vaccinated and unvaccinated group. Sample size of the random sample, per group, was calculated using the formula to estimate a proportion assuming that 90% of those who self-reported being vaccinated or unvaccinated status were truly vaccinated or unvaccinated, respectively [@b0185]. The sample size in each group was 123 and 128 for the vaccinated and unvaccinated groups, respectively. For each selected mother, we reviewed vaccination records of the Expanded Program on Immunization at the Health Unit where the mother received antenatal care and/or we contacted the mother and documented the vaccination date directly from the vaccination card (during a home visit) or as reported by the mother reading from the card (by telephone); influenza vaccination was considered confirmed if an exact date for vaccination could be provided by any of these methods. Likewise, non-vaccination status was corroborated if no information on vaccination including specific date for vaccination was identified from these sources. The positive predictive value (PPV) and negative predictive value (NPV) of self-reporting vaccination and non-vaccination status were then calculated. Out of all participants randomly selected for this assessment who self-reported receiving influenza vaccination (n = 123), 61% (75) had evidence of vaccination. Of the total (n = 128) of participants who self-reported not receiving influenza vaccination, only 2 (2%), had evidence of influenza vaccination. Thus, PPV was 61% (75/123) for self-reporting receiving influenza vaccination, and NPV was 98% (126/128) for self-reports of being unvaccinated. Due to the low PPV and high NPV, we excluded from further analyses women who self-reported vaccination status but did not present evidence of vaccination, and we included all participants who self-reported non-vaccination status.

2.2. Data analysis {#s0040}
------------------

### 2.2.1. Variable definitions {#s0045}

Age was categorized into three groups: \<18, 18--34 and ≥35 years old. A proxy variable was calculated for cumulative influenza exposure using influenza surveillance data from Nicaragua [@b0190]. This variable was calculated in stages, first by dividing the number of positive influenza samples by the total number of samples tested per week from the surveillance data and then assigning the cumulative sum of the influenza positive proportions per week to the weeks that women were pregnant; we dichotomized this variable by high or low exposure using the median cumulative influenza exposure as a cutoff. Birth outcome data were defined and calculated as follows: (1) gestational age at delivery was calculated using LMP, if available, or gestational age at any ultrasound obtained from antenatal medical records (see [Supplementary material A1](#s0100){ref-type="sec"} for gestational age calculation algorithm); (2) small for gestational age (SGA) was calculated from weight and gestational age at delivery according to the International Fetal and Newborn Growth Consortium for the 21st Century, or intergrowth-21st standards [@b0180]; (3) preterm birth (PTB) was defined as born with \<37 weeks of gestational age; and (4) low birth weight (LBW) was defined as born weighing \<2500 g.

2.3. Statistical analysis {#s0050}
-------------------------

We compared all variables by vaccination status using chi-square test to compare differences between vaccinated and unvaccinated women regardless of trimester of receipt of influenza vaccination. We performed multivariable logistic regression (MLR) analyses per birth outcome (SGA, PTB and LBW) as the variable of interest and influenza vaccination as the exposure variable. We used the Akaike Information criterion (AIC) to identify the most parsimonious model. In addition, we performed propensity score matching (PSM) to control for the individual differences in probability of being vaccinated. Variables included in the PSM model that could explain probability of receiving vaccination were selected *a priori* (age, race, education level, number of antenatal visits, reporting at least one chronic condition (obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease) and because of a crude association with vaccination and/or birth outcomes (type of fuel used for cooking, number of people in the household, reporting receiving at least one tetanus vaccine, iron and vitamin B12 consumption during pregnancy, albendazole consumption during pregnancy, calcium consumption during pregnancy, aspirin consumption during pregnancy, alcohol consumption before pregnancy, body mass index (BMI) calculated from height and weight measurements taken at first antenatal visit, number of parturitions). For PSM, we used the nearest neighbor approach that requires one-to-two vaccinated-to-unvaccinated proportion for good propensity score matching [@b0195]. When the requirement was not met, we randomly sampled from the vaccinated cases to obtain an unvaccinated to vaccinated ratio greater than one. We repeated the random sample selection a thousand times; point estimate and lower and upper 95% confidence intervals represent 50th, 2.5th and 97.5th percentiles, respectively [@b0200]. PSM matched one vaccinated case to one unvaccinated case for the probability of vaccination. After PSM, we evaluated these variables for significant differences between the vaccination status groups in order to know how well matching occurred. We then evaluated the association of influenza vaccination and birth outcomes by MLR models, including variables measured after-vaccination: delivery hospital, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), reporting at least one episode of influenza-like illness during pregnancy (ILI), alcohol consumption before pregnancy, number of parturitions, sex of the baby, and influenza circulation.

As a secondary investigation, we assessed the association of influenza vaccination and birth outcomes by trimester in which women received influenza vaccination; the unvaccinated group was used as a control for all models. We present adjusted odds ratios (aORs), as well as 95% confidence intervals and p-values. As a sensitivity analysis, we repeated the analyses including all women who self-reported vaccination, regardless of proof of evidence. All analyses were performed in R software (R version 3.2.2).

### 2.3.1. Ethics statement {#s0055}

The Institutional Review Board at the Nicaraguan Ministry of Health reviewed and approved the protocol. The protocol was also reviewed at the Centers for Disease Control and Prevention and was determined to be public health practice-program evaluation.

3. Results {#s0060}
==========

3.1. Descriptive analysis {#s0065}
-------------------------

From July 21st through December 4th 2014, we interviewed and collected surveys on 4808 post-partum women. After exclusions, a final sample of 3268 women was included in the analysis ([Fig. 1](#f0005){ref-type="fig"}). [Fig. 2](#f0010){ref-type="fig"} shows timing of influenza vaccination (Trivalent inactivated influenza vaccine, southern hemisphere formulation) with respect to influenza circulation in the country; most participants (96%) received influenza vaccination before the peak of influenza circulation in August through November 2014.Fig. 1Exclusion criteria and data cleaning algorithm.Fig. 2Number of surveyed women at delivery, number of pregnant women vaccinated for month stratified by trimester of vaccination, and proportion of influenza positive samples from routine surveillance^\*^, Nicaragua 2014 ^\*^Proportions of influenza positive samples from routine surveillance correspond to year 2014. Average level of influenza activity corresponds to years 2011--2013 (Nicaragua, national influenza surveillance data, Severe Acute Respiratory Infections network, SARInet, PAHO).

Of the 3268 women included in the analysis, 55% (1789) had documented influenza vaccination in 2014. Of those, 8% (137) were vaccinated in their first trimester, 61% (1093) in their second trimester, and 31% (559) in their third trimester.

Overall, 13% (415) were younger than 18 years (range: 12--17), 80% (2620) were between 18 and 34 years, and 7% (233) were 35 years and older (range: 35--45; [Table 1](#t0005){ref-type="table"}). Ninety-seven percent (3172) reported having at least one antenatal visit during pregnancy, 78% (2549) reported four or more antenatal visits, and 91% (2984) reported having at least one dose of tetanus vaccine; all of these antenatal care indicators were significantly more common among vaccinated compared to unvaccinated women.Table 1Selected characteristics of participant pregnant women (n = 3268), post-partum interview, July--December 2014, Managua Province, Nicaragua.AllVaccinatedUnvaccinatedp-value[†](#tblfn1){ref-type="table-fn"}n = 3268n = 1789n = 1479n (%)n (%)n (%)Age \<18 years415 (13)232 (13)183 (12)0.80 18--34 years2620 (80)1433 (80)1187 (80) ≥35 years233 (7)124 (7)109 (7)  Number of persons in household 2--4898 (27)528 (30)370 (25)0.02 5--61070 (33)580 (32)490 (33) 7--8707 (22)381 (21)326 (22) \>8593 (18)300 (17)293 (20)Delivered at reference[\*](#tblfn3){ref-type="table-fn"}obstetric hospital1722 (53)1083 (61)639 (43)\<0.01Education level No education/primary school incomplete421 (13)231 (13)190 (13)0.01 Primary school complete337 (10)195 (11)142 (10) Secondary school incomplete1372 (42)771 (43)601 (41) Secondary school complete637 (19)353 (20)284 (19) Technical/university studies501 (15)239 (13)262 (18)  Received at least one dose of tetanus vaccine2984 (91)1759 (98)1225 (83)\<0.01At least one antenatal visits3172 (97)1786 (100)1386 (94)\<0.01Four or more antenatal visits2549 (78)1542 (86)1007 (68)\<0.01Gestational age at first antenatal visit (median, quantiles in weeks)12 (9, 19)12 (9, 17)13 (9, 22)\<0.01[‡](#tblfn2){ref-type="table-fn"}Consumption of iron and folic acid1485 (45)805 (45)680 (46)0.59Consumption of albendazol703 (22)482 (27)221 (15)\<0.01Consumption of calcium1243 (38)722 (40)521 (35)\<0.01Consumption of aspirin938 (29)600 (34)338 (23)\<0.01  BMI (height and weight measured at 1st antenatal visit) Underweight (\<18.5)315 (10)116 (6)199 (13)\<0.01 Normal weight (18.5--24.9)1338 (41)808 (45)530 (36) Overweight (25--29.9)928 (28)510 (29)418 (28) Obesity I (30--34.9)408 (12)224 (13)184 (12) Obesity II (35--39.9)163 (5)87 (5)76 (5) Extreme obesity (\>40)88 (3)41 (2)47 (3)  Alcohol consumption before pregnancy441 (13)220 (12)221 (15)0.05Renal Disease1266 (39)734 (41)532 (36)\<0.01Blood Disease743 (23)445 (25)298 (20)\<0.01At least one chronic condition[\*\*](#tblfn4){ref-type="table-fn"}1855 (57)1069 (60)786 (53)\<0.01  Number of parturitions 11519 (46)879 (49)640 (43)\<0.01 2--31447 (44)768 (43)679 (46) \>3302 (9)142 (8)160 (11)  Female1585 (49)804 (45)781 (53)\<0.01Preterm birth175 (5)95 (5)80 (5)0.96Small for gestational age343 (10)198 (11)145 (10)0.26Low birth weight195 (6)99 (6)96 (6)0.28[^1][^2][^3][^4]

More than half of the surveyed women (57%) reported having at least one chronic condition (obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease); conditions were more common among vaccinated (60%) than unvaccinated women (53%) (p-value \< 0.01). Overall, for approximately half of the participants (46%) the baby included in the study was their first; however, being a first-time mother was more frequent among those vaccinated than unvaccinated (49% vs. 43%, respectively). Finally, adverse birth outcomes were infrequent among the participants and did not differ by vaccination status (p-value \> 0.05); the percentage with preterm birth was 5%, small for gestational age was 10% and low birth weight was 6% ([Table 1](#t0005){ref-type="table"}). However, only among participants vaccinated in the first trimester, the percentage with preterm birth was 12%, significantly higher than the unvaccinated group (6%; p-value \< 0.05; [Supplementary material A2](#s0100){ref-type="sec"}).

3.2. Regression analysis {#s0070}
------------------------

After adjusting for risk factors, we did not find an association between receiving influenza vaccination and birth outcomes with either of the two different analytical approaches. With the MLR models, the adjusted ORs and their respective 95% CIs for SGA, PTB, and LWB were 1.03 (0.82--1.31), 0.95 (0.75--1.20), and 0.89 (0.66--1.22). We obtained similar results with PSM ([Table 2](#t0010){ref-type="table"}).Table 2Evaluation of the association of influenza vaccination and birth outcomes among pregnant women by trimester of vaccination (n = 3268), post-partum interview, July--December 2014, Managua Province, Nicaragua.Birth outcomesInfluenza vaccine 2014 seasonInfluenza vaccine 2014 seasonMultiple Logistic Regression (MLR)Propensity score Model (PSM)[†](#tblfn8){ref-type="table-fn"} + MLR[ǂ](#tblfn9){ref-type="table-fn"} n = 1600 × 1000 simulations[¥](#tblfn10){ref-type="table-fn"}aOR (95% CI)aOR (95% CI)Small for gestational age (SGAi)1.03[\*](#tblfn5){ref-type="table-fn"}(0.82; 1.31)1.02(0.83; 1.24)Preterm birth (PTB)0.95[\*\*](#tblfn6){ref-type="table-fn"}(0.75; 1.20)0.88(0.73; 1.06)Low birth weight (LBW)0.89[\*\*\*](#tblfn7){ref-type="table-fn"}(0.66; 1.22)0.83(0.62; 1.06)[^5][^6][^7][^8][^9][^10][^11]

[Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"} present results by trimester of influenza vaccination for the MLR and PSM models, respectively. In both models, we observed a trend whereby the later in pregnancy a women received vaccination the lower her adjusted odds of PTB. This was not statistically significant in the MLR models. However, the protective effect of influenza vaccination on PTB among those receiving vaccination in their second and third trimester was significant with PSM (aOR: 0.87; 95% CI: 0.75--0.99 and aOR: 0.66; 95% CI: 0.45--0.96, respectively; [Table 4](#t0020){ref-type="table"}). In addition, we found a protective effect of influenza vaccination on LBW among those vaccinated in the second trimester (aOR: 0.80; 95%CI: 0.64--0.97) using PSM. Further analyses including those who self-reported vaccination showed similar trends (see [Supplementary materials A3-A5](#s0100){ref-type="sec"}). No other significant associations between birth outcomes and vaccination by trimester were noted.Table 3Evaluation of the association of influenza vaccination and birth outcomes among pregnant women by trimester of vaccination (n = 3268) with multiple logistic regression (MLR) method, post-partum interview, July--December 2014, Managua, Nicaragua.Birth outcomesInfluenza vaccine 2014 seasonVaccinated in first trimester (n = 140)Vaccinated in second trimester (n = 1142)Vaccinated in third trimester (n = 581)aOR (95% CI)p-valueaOR (95% CI)p-valueaOR (95% CI)p-valueSmall for gestational age[\*](#tblfn11){ref-type="table-fn"} (SGAi)1.13(0.66; 1.94)0.661.03(0.79; 1.34)0.820.92(0.65; 1.30)0.64Preterm birth[\*\*](#tblfn12){ref-type="table-fn"} (PTB)1.43(0.86; 2.39)0.170.91(0.70; 1.17)0.450.86(0.62; 1.18)0.35Low birth weight (LBW)[\*\*\*](#tblfn13){ref-type="table-fn"}1.56(0.81; 3.02)0.190.88(0.61; 1.26)0.480.85(0.55; 1.32)0.47[^12][^13][^14][^15]Table 4Evaluation of the association of influenza vaccination and birth outcomes among pregnant women by trimester of vaccination with propensity score matching (PSM) analysis[\*](#tblfn14){ref-type="table-fn"}, post-partum interview, July--December 2014, Managua, Nicaragua.Birth outcomesInfluenza vaccine 2014 seasonVaccinated in first trimester (n = 280)Vaccinated in second trimester (n = 1600)Vaccinated in third trimester (n = 1162)aOR (95% CI)aOR (95% CI) ×1000sim[\*\*\*](#tblfn16){ref-type="table-fn"}aOR (95% CI)Small for gestational age (SGA)0.90(0.40; 2.03)1.00(0.86; 1.17)0.83(0.55; 1.25)Preterm birth[\*\*](#tblfn15){ref-type="table-fn"} (PTB)1.67(0.73; 3.83)**0.87(0.75; 0.99)0.66(0.45; 0.96)**Low birth weight (LBW)[\*\*](#tblfn15){ref-type="table-fn"}1.71(0.55; 5.26)**0.80(0.64; 0.97)**0.64(0.38; 1.09)[^16][^17][^18][^19]

4. Discussion {#s0075}
=============

The present study did not find an association between maternal influenza vaccination administered at any point in pregnancy and adverse birth outcomes among their babies. However, in secondary analyses stratifying influenza vaccination by trimester we observed a protective effect of vaccination on PTB in the second and third trimester and on LBW in the second trimester. Although there is a possibility that vaccination can explain these protective effects, observational studies have inherent biases that preclude them from establishing causality [@b0205], [@b0210].

Using PSM, we observed a protective effect of influenza vaccination on PTB and LBW among those vaccinated in the second and third trimester. Although not statistically significant, the MLR approach also trended in the same direction. Likely, the analysis with PSM corrected for biases related to the probability of influenza vaccination by controlling for differences between vaccinated and unvaccinated women that we were not able to control for in MLR [@b0215]. Our findings are consistent with a number of studies that found an association between receiving influenza vaccination and reduced likelihood of delivering a baby PTB or with LBW [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105], [@b0110]. In addition, a recent meta-analysis found a strong association between receipt of influenza vaccination and reduced likelihood of PTB and LBW, and the magnitude of the association that Nunes et al. reported was comparable to our findings [@b0220].

On the other hand, numerous other studies report a lack of association between influenza vaccination and birth outcomes [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0145], [@b0150]. Two of these studies used similar methods to our study. Nordin et al. analyzed the large Vaccine Safety Datalink dataset (n = 57,554 pregnant women in the United States) to assess these associations and after using propensity score to minimize bias introduced by the probability of being vaccinated found no association between influenza vaccination during pregnancy and risk of SGA or PTB [@b0130]. In Finland, Baum et al. also did not find an association when analyzing retrospective data by trimester of vaccination and applying propensity score to account for the probability of vaccination; however, this study was performed during the 2009 pandemic so may not be directly comparable [@b0145]. Overall, differences in study design, populations, influenza virus and circulation variability make it a challenge to compare results [@b0155].

Observational studies like ours are subject to potential residual confounding, and Vazquez-Benitez et al. [@b0215] demonstrated that not accounting for biases in observational data can mislead the results. In our study, in addition to social desirability or recall bias on key variables like chronic conditions, there may have been residual confounding as we did not collect information on other risk factors known to be associated with adverse neonatal outcomes, such as previous history of adverse birth outcomes, domestic violence, harsh working conditions, or exposure to pollutants or chemicals [@b0225], [@b0230], [@b0235], [@b0240], [@b0245], [@b0250]. In addition, we lacked specific information regarding the timing of antenatal supplements or health complications during pregnancy, and the literature shows that the timing of these events with respect to trimester of gestation could be associated with birth outcomes [@b0255], [@b0260].

We acknowledge the following limitations. First, from 2007--2013, the Government of Nicaragua provided influenza vaccination only for pregnant women with chronic conditions [@b0170]. In 2013, the influenza vaccination recommendation was extended to all pregnant women in the Municipality of Managua, and in 2014, the Government of Nicaragua extended influenza vaccination to all pregnant women in the country. However, little is known about how well the recommendations were implemented. Indeed, vaccine uptake remained somewhat higher among pregnant women with pre-existing chronic medical conditions in our study year suggesting that the recommendation may have been slow to take effect. Higher vaccination among pregnant women with high-risk pregnancies could have caused a selection bias as those vaccinated women would have been at higher risk for adverse pregnancy outcomes compared to unvaccinated women. Second, the sample was not randomly selected. Women who agreed to participate in the study could have been different from women who did not participate in the study, and we did not collect characteristics on women who refused to participate in the study to ascertain this bias. Third, we did not power the sample size to analyze effects by trimester of vaccination and so may have missed important effects. Fourth, we based our calculation of gestational age at delivery on LMP which is known to be subject to recall bias and could have introduced errors in our calculations [@b0265]. However, when LMP was determined to be unreliable, we calculated gestational age at delivery using data from an ultrasound. Approximately 6% of the gestational age estimates came from ultrasounds in the last trimester, which have higher rates of estimate error than estimates calculated in early pregnancy. Finally, we were not able to obtain information on previous pregnancy outcomes; previous history of PTB or abortion in the second trimester has been associated with an increased frequency of PTB [@b0270].

Despite these limitations, the strengths of our study include having access to birth outcomes from medical records as well as having available influenza surveillance data. Studies suggest that the effect of influenza vaccination on birth outcomes may be better observed during high influenza circulation period, and there was a substantial influenza circulation in Nicaragua in 2014 [@b0100], [@b0105], [@b0275]. Furthermore, the propensity score analyses minimized biases introduced by differences in baseline characteristics between unvaccinated and vaccinated pregnant women by accounting for the probability of vaccination based on these characteristics [@b0215]. We were also able to perform sensitivity analysis for self-reported vaccination. Moreover, we used international standards to define the variable small for gestational age [@b0180] and validated it with a World Health Organization calculator to estimate SGA [@b0280]; results were consistent for both (data not shown).

In summary, we found some evidence of a protective effect of influenza vaccination by trimester on birth outcomes; however, we encourage further investigation by prioritizing prospective cohort designs over retrospective studies to minimize selection and recall biases. In addition, it may be helpful for countries to assess knowledge, attitudes and practices of influenza vaccination recommendations among health personnel, especially in countries where influenza vaccination recommendations and practices have recently been implemented or expanded.
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[^1]: X^2^ test.

[^2]: Wilcoxon test.

[^3]: Reference obstetric hospital in Nicaragua: Hospital Bertha Calderon Roque.

[^4]: At least one chronic condition of the following: obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease.

[^5]: aOR = Adjusted Odds Ratio.

[^6]: Model adjusted for reporting at least one chronic condition (obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease), age, race, calcium, iron, and folic acid consumption during pregnancy, education level, number of parturitions, body mass index (BMI) at first antenatal visit, and sex of the baby.

[^7]: Model adjusted for reporting at least one chronic condition (obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease), age, albendazol and aspirin consumption during pregnancy, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), delivery hospital, number of parturitions, body mass index (BMI) at first antenatal visit, alcohol consumption before pregnancy, number of antenatal visits, and sex of the baby.

[^8]: Model adjusted for delivery hospital, number of parturitions, education level, alcohol consumption before pregnancy, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), body mass index (BMI) at first antenatal visit, sex of the baby, and number of antenatal visits.

[^9]: Propensity Score Models adjusted for age, race, education level, type of fuel used for cooking, number of people in the household, reporting receiving at least one tetanus vaccine, number of antenatal visits, Fe and vitamin B12 consumption during pregnancy, albendazol consumption during pregnancy, calcium consumption during pregnancy, aspirin consumption during pregnancy, alcohol consumption before pregnancy, body mass index (BMI) at first antenatal visit, number of parturitions, and reporting at least one chronic condition (obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease).

[^10]: Models adjusted for delivery hospital, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), reporting at least one episode of influenza-like illness during pregnancy (ILI), alcohol consumption before pregnancy, number of parturitions, sex of the baby, and influenza circulation.

[^11]: Based on 1000 simulations when requirement one-to-two vaccinated-to-unvaccinated proportion for good propensity score matching was not met; point estimate and lower and upper confidence interval represent 50th, 25th and 97.5th percentiles of point estimates (n = 1000), respectively.

[^12]: aOR = Adjusted Odds Ratio.

[^13]: Models adjusted for race, education level, iron and folic acid consumption during pregnancy, number of parturitions, body mass index (BMI) at first antenatal visit, number of antenatal visits and sex of the baby for mothers vaccinated in the first trimester; age, race, education level, iron and folic acid consumption during pregnancy, number of parturitions, body mass index (BMI) at first antenatal visit, number of antenatal visits, number of people in the household and sex of the baby for mothers vaccinated in the second trimester; number of parturitions, body mass index (BMI) at first antenatal visit, reporting at least one chronic condition (obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease) and sex of the baby for mothers vaccinated in the third trimester.

[^14]: Models adjusted for alcohol consumption before pregnancy, BMI at first antenatal visit, number of antenatal visits, albendazol consumption during pregnancy, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), delivery hospital, sex of the baby, type of fuel used for cooking, reporting receiving at least one tetanus vaccine, number of parturitions, education level, age, reporting at least one episode of influenza-like illness during pregnancy (ILI), race and reporting at least one chronic condition for mothers vaccinated in the first trimester; alcohol consumption before pregnancy, BMI at first antenatal visit, influenza circulation, aspirin consumption during pregnancy, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), delivery hospital, and, number of antenatal visits for mothers vaccinated in the second trimester; alcohol consumption before pregnancy, BMI at first antenatal visit, number of antenatal visits, albendazol consumption during pregnancy, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), delivery hospital, sex of the baby, race and reporting at least one chronic condition for mothers vaccinated in the third trimester.

[^15]: Models adjusted for alcohol consumption before pregnancy, BMI at first antenatal visit, number of antenatal visits, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), delivery hospital, sex of the baby, and ILI for mothers vaccinated in the first trimester; education level, alcohol consumption before pregnancy, BMI at first antenatal visit, number of antenatal visits, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), delivery hospital, sex of the baby, number of parturitions, and ILI for mothers vaccinated in the second trimester; alcohol consumption before pregnancy, BMI at first antenatal visit, number of antenatal visits, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), and sex of the baby for mothers vaccinated in the third trimester.

[^16]: aOR = Adjusted Odds Ratio.

[^17]: Propensity Score Models adjusted for age, race, education level, type of fuel used for cooking, number of people in the household, reporting receiving at least one tetanus vaccine, number of antenatal visits, Fe and vitamin B12 consumption during pregnancy, albendazol consumption during pregnancy, calcium consumption during pregnancy, aspirin consumption during pregnancy, alcohol consumption before pregnancy, body mass index (BMI) at first antenatal visit, number of parturitions, and reporting at least one chronic condition (obesity, diabetes, asthma, renal disease, liver disease, blood disease, neurologic disease).

[^18]: Models adjusted for delivery hospital, hospitalization during pregnancy for any specific complication (preeclampsia, eclampsia, hemorrhage, sepsis, urinary infection, diabetes, severe acute respiratory infection), reporting at least one episode of influenza-like illness during pregnancy (ILI), alcohol consumption before pregnancy, number of parturitions, sex of the baby, and influenza circulation.

[^19]: Based on 1000 simulations when requirement one-to-two vaccinated-to-unvaccinated proportion for good propensity score matching was not met; point estimate and lower and upper confidence interval represent 50th, 25th and 97.5th percentiles of point estimates (n = 1000), respectively.
